Marksans Pharma Limited

NSEI:MARKSANS Voorraadrapport

Marktkapitalisatie: ₹139.9b

Marksans Pharma Dividenden en inkoop

Dividend criteriumcontroles 3/6

Marksans Pharma is een dividendbetalend bedrijf met een huidig rendement van 0.19% dat ruimschoots wordt gedekt door de winst.

Belangrijke informatie

0.2%

Dividendrendement

0.05%

Terugkoop Rendement

Totaal aandeelhoudersrendement0.2%
Toekomstig dividendrendement1.1%
Dividendgroei5.0%
Volgende betaaldatum dividendn/a
Ex-dividenddatumn/a
Dividend per aandeel₹0.600
Uitbetalingsratio9%

Recente updates van dividend en inkoop

Recent updates

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06
What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: De dividendbetalingen van MARKSANS zijn de afgelopen 10 jaar volatiel geweest.

Groeiend dividend: De dividendbetalingen van MARKSANS zijn de afgelopen 10 jaar gestegen.


Dividendrendement versus markt

Marksans Pharma Dividendrendement versus markt
Hoe verhoudt MARKSANS dividendrendement zich tot de markt?
SegmentDividendrendement
Bedrijf (MARKSANS)0.2%
Markt onderkant 25% (IN)0.3%
Markt Top 25% (IN)1.2%
Gemiddelde industrie (Pharmaceuticals)0.7%
Analist prognose (MARKSANS) (tot 3 jaar)1.1%

Opmerkelijk dividend: Het dividend van MARKSANS ( 0.19% ) is niet noemenswaardig vergeleken met de onderste 25% van de dividendbetalers op de Indian markt ( 0.25% ).

Hoog dividend: Het dividend MARKSANS ( 0.19% ) is laag vergeleken met de top 25% van dividendbetalers in de Indian markt ( 1.15% ).


Winstuitkering aan aandeelhouders

Verdiendekking: Met zijn lage payout ratio ( 8.7% ) worden de dividendbetalingen van MARKSANS grotendeels gedekt door de winst.


Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Met zijn redelijke cash payout ratio ( 52.3% ) worden de dividendbetalingen van MARKSANS gedekt door kasstromen.


Ontdek bedrijven met een sterk dividend